Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
gptkb:amantadine
1-aminoadamantane |
| gptkbp:CASNumber |
gptkb:768-94-5
|
| gptkbp:contains_functional_group |
amphetamine
|
| gptkbp:has_parent_structure |
adamantane
|
| gptkbp:hasInChIKey |
InChI=1S/C10H17N/c11-10-5-1-8-2-6(10)4-9(10)3-7(8)1/h1-9H2,11H2
DDFLSUZHGBQRHG-UHFFFAOYSA-N |
| gptkbp:hasMolecularFormula |
gptkb:C10H17N
|
| gptkbp:hasSMILES |
NC1C2CC3CC(C2)CC1C3
|
| gptkbp:hasUNII |
U7A4V6E0D8
|
| https://www.w3.org/2000/01/rdf-schema#label |
adamantan-1-amine
|
| gptkbp:IUPACName |
gptkb:adamantan-1-amine
|
| gptkbp:meltingPoint |
110–113 °C
|
| gptkbp:PubChem_CID |
2130
2618 2046 DB00915 |
| gptkbp:usedFor |
antiviral drug
treatment of Parkinson's disease |
| gptkbp:bfsParent |
gptkb:1-adamantanamine
|
| gptkbp:bfsLayer |
7
|